Metabolism of ethylbenzene by human liver microsomes and recombinant human cytochrome P450s (CYP)

Toxicology Letters

Volumn 147, Issue 3, 2004, Pages 253-260

  Sams, Craig ^a   Loizou, George D ^a   Cocker, John ^a   Lennard, Martin S ^b  

^a HEALTH AND SAFETY LABORATORY   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Biological monitoring; Cytochrome P450; Ethylbenzene

Indexed keywords

1 PHENYLETHANOL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2E1; CYTOCHROME P450 INHIBITOR; DIETHYLDITHIOCARBAMIC ACID; ETHYLBENZENE; LIVER ENZYME;

ARTICLE; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN TISSUE; HYDROXYLATION; LIVER METABOLISM; LIVER MICROSOME; PRIORITY JOURNAL;

EID: 0842346020     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2003.11.010     Document Type: Article

References (29)

1. ACGIH, 2000. Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices, Cincinnati.
2. Bardodej Z., Bardodejova E. Biotransformation of ethylbenzene, styrene and alpha-methylstyrene in man. Am. Ind. Hyg. Assoc. J. 31:1970;206-209.
3. Blaauboer B.J. The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic as modelling a tool in hazard and risk assessment. A commentary. Toxicol. Lett. 138:2003;161-171.
4. Busby W.F., Ackermann J.M., Crespi C.L. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA expressed human cytochromes P-450. Drug Metab. Dispos. 27:1999;246-249.
5. Cavender, F., 1994. Ethylbenzene. In: Claydon, G., Claydon, F. (Eds.), Patty's Industrial Hygiene and Toxicology. Wiley/Interscience, New York, pp. 1342-1346.
6. Chauret N., Gauthier A., Nicoll-Griffith D.A. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab. Dispos. 26:1998;1-4.
7. de la Maza M.P., Hirsch S., Petermann M., Suazo M., Ugarte G., Bunout D. Changes in microsomal activity in alcoholism and obesity. Alcohol. Clin. Exp. Res. 24:2000;605-610.
8. Eagling V.A., Tjia J.F., Back D.J. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol. 45:1998;107-114.
9. Engstrom K., Riihimaki V., Laine A. Urinary disposition of ethylbenzene and m-xylene in man following separate and combined exposure. Int. Arch. Occup. Environ. Health. 54:1984;355-363.
10. Farrell G. Effects of disease on expression and regulation of CYPs. Mol. Aspects Med. 20:1999;55-70.
11. Fishbein L. An overview of environmental and toxicological aspects of aromatic hydrocarbons IV. Ethylbenzene. Sci. Tot. Environ. 44:1985;269-287.
12. Gebhardt A.C., Lucas D., Menez J.F., Seitz H.K. Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology. 26:1997;957-961.
13. Gromiec J.P., Piotrowski J.K. Urinary mandelic acid as an exposure test for ethylbenzene. Int. Arch. Occup. Environ. Health. 55:1984;61-72.
14. Guengerich F.P., Kim D.H., Iwasaki M. Role of human cytochrome P-450 IIEI in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4:1991;168-179.
15. Hissink E.M., Bogaards J.J.P., Freidig A.P., Commandeur J.N.M., Vermeulen N.P.E., van Bladeren P.J. The use of in vitro metabolic parameters and physiologically based pharmacokinetic (PBPK) modeling to explore the risk assessment of trichloroethylene. Environ. Toxicol. Pharm. 11:2002;259-271.
16. Houston J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47:1994;1469-1479.
17. Kadlubar F.F., Guengerich F.P. Inducibility of human cytochromes P-450 primarily involved in the activation of chemical carcinogens. Chemosphere. 25:1992;201-204.
18. Kharasch E.D., Thummel K.E., Mhyre J., Lillibridge J.H. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clin. Pharmacol. Ther. 53:1993;643-650.
19. Kim H., Wang R.S., Elovaara E., Raunio H., Pelkonen O., Aoyama T., Vainio H., Nakajima T. Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica. 27:1997;657-665.
20. Lauwerys, R.R., Hoet, P., 2001. Industrial Chemical Exposure: Guidelines for Biological Monitoring. Lewis Publishers, Boca Raton, FL.
21. Lipscomb J.C., Kedderis G.L. Incorporating human interindividual biotransformation variance in health risk assessment. Sci. Tot. Environ. 288:2002;13-21.
22. Loizou G.D., Cocker J. The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone. Hum. Exp. Toxicol. 20:2001;321-327.
23. MacGregor J.T., Collins J.M., Sugiyama Y., Tyson C.A., Dean J., Smith L., Andersen M., Curren R.D., Houston J.B., Kadlubar F.F., Kedderis G.L., Krishnan K., Li A.P., Parchment R.E., Thummel K., Tomaszewski J.E., Ulrich R., Vickers A.E.M., Wrighton S.A. In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicol. Sci. 59:2001;17-36.
24. Nakajima T., Elovaara E., Gonzalez F.J., Gelboin H.V., Raunio H., Pelkonen O., Vainio H., Aoyama T. Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450. Chem. Res. Toxicol. 7:1994;891-896.
25. Newton D.J., Wang R.W., Lu A.Y.H. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23:1995;154-157.
26. Sai Y., Dai Y., Yang T.J., Krausz K.W., Gonzalez F.W., Gelboin H.V., Shous M. Assessment of specificity of eight chamical inhibitors using cDNA expressed cytochromes P450. Xenobiotica. 30:2000;327-343.
27. Tassaneeyakul W., Birkett D.J., Edwards J.W., Veronese M.E., Tassaneeyakul W., Tukey R.H., Miners J.O. Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene. J. Pharmacol. Exp. Ther. 276:1996;101-108.
28. Venkatakrishnan K., von Moltke L.L., Court M.H., Harmatz J.S., Crespi C.L., Greenblatt D.J. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos. 28:2000;1493-1504.
29. WHO, 1996. Environmental Health Criteria 186. Ethylbenzene, World Health Organisation, Geneva.